Carole Fakhry1,2,3, Martin Krapcho4, David W Eisele1, Gypsyamber D'Souza3. 1. Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medicine, Baltimore, Maryland. 2. Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, Baltimore, Maryland. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Information Management Systems Inc, Calverton, Maryland.
Abstract
BACKGROUND: The increasing incidence of oropharyngeal squamous cell cancer (OPSCC) is well established. However, up-to-date incidence estimates and trends for head and neck squamous cell cancers (HNSCCs) overall, including major anatomic sites, and nonoropharyngeal (non-OP) HNSCCs by sex, race, and age in the United States are not well described. METHODS: A retrospective analysis of incident HNSCCs during 1992 through 2014 using the Surveillance, Epidemiology, and End Results database was performed to evaluate the incidence of HNSCCs overall, OPSCC, and non-OP HNSCC (those of the larynx, oral cavity, hypopharynx, nasopharynx, and nasal cavity). Incidence rates were calculated overall and by subgroups of interest, and incidence rate ratios were used to compare rates between groups. The incidence rates presented were per 100,000 population and were age adjusted to the 2000 US standard population (19 age groups; Census P25-1130). The annual percent change (APC) was modeled with and without joinpoints. RESULTS: The incidence of HNSCC overall declined (average APC [aAPC], -0.8; P<.001) despite significant increases in the incidence of OPSCCs, most notably between 2000 and 2014 (APC, 2.1; P<.001). Significant declines in incidence were observed for all non-OP HNSCC sites for both women and men (P<.001 each). Among women, the risk of OPSCC also significantly decreased (aAPC, -0.8; P = .002), whereas the risk among men was stable during 1992 through 2001 (APC, 0.4; P = .42) and then significantly increased from 2001 to 2014 (APC, 2.7; P<.001). Decreases in the risk of non-OP HNSCC were especially large for black women (aAPC, -2.6; P<.001) and men (aAPC, -3.0; P<.001). Although the incidence of HNSCC previously was highest among black individuals, since 2009 its incidence has been higher among white compared with black individuals. CONCLUSIONS: The incidence of HNSCC is declining, especially for non-OP HNSCC and among black individuals. Cancer 2018;124:2125-33.
BACKGROUND: The increasing incidence of oropharyngeal squamous cell cancer (OPSCC) is well established. However, up-to-date incidence estimates and trends for head and neck squamous cell cancers (HNSCCs) overall, including major anatomic sites, and nonoropharyngeal (non-OP) HNSCCs by sex, race, and age in the United States are not well described. METHODS: A retrospective analysis of incident HNSCCs during 1992 through 2014 using the Surveillance, Epidemiology, and End Results database was performed to evaluate the incidence of HNSCCs overall, OPSCC, and non-OP HNSCC (those of the larynx, oral cavity, hypopharynx, nasopharynx, and nasal cavity). Incidence rates were calculated overall and by subgroups of interest, and incidence rate ratios were used to compare rates between groups. The incidence rates presented were per 100,000 population and were age adjusted to the 2000 US standard population (19 age groups; Census P25-1130). The annual percent change (APC) was modeled with and without joinpoints. RESULTS: The incidence of HNSCC overall declined (average APC [aAPC], -0.8; P<.001) despite significant increases in the incidence of OPSCCs, most notably between 2000 and 2014 (APC, 2.1; P<.001). Significant declines in incidence were observed for all non-OP HNSCC sites for both women and men (P<.001 each). Among women, the risk of OPSCC also significantly decreased (aAPC, -0.8; P = .002), whereas the risk among men was stable during 1992 through 2001 (APC, 0.4; P = .42) and then significantly increased from 2001 to 2014 (APC, 2.7; P<.001). Decreases in the risk of non-OP HNSCC were especially large for black women (aAPC, -2.6; P<.001) and men (aAPC, -3.0; P<.001). Although the incidence of HNSCC previously was highest among black individuals, since 2009 its incidence has been higher among white compared with black individuals. CONCLUSIONS: The incidence of HNSCC is declining, especially for non-OP HNSCC and among black individuals. Cancer 2018;124:2125-33.
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Sagar C Patel; William R Carpenter; Seth Tyree; Marion Everett Couch; Mark Weissler; Trevor Hackman; D Neil Hayes; Carol Shores; Bhishamjit S Chera Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Christine G Gourin; Arlene A Forastiere; Giuseppe Sanguineti; Shanthi Marur; Wayne M Koch; Robert E Bristow Journal: Laryngoscope Date: 2011-04 Impact factor: 3.325
Authors: John M David; Allen S Ho; Michael Luu; Emi J Yoshida; Sungjin Kim; Alain C Mita; Kevin S Scher; Stephen L Shiao; Mourad Tighiouart; Zachary S Zumsteg Journal: Cancer Date: 2017-06-22 Impact factor: 6.860
Authors: Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison Journal: J Clin Oncol Date: 2014-12-08 Impact factor: 44.544
Authors: Gypsyamber D'Souza; William H Westra; Steven J Wang; Annemieke van Zante; Alicia Wentz; Nicole Kluz; Eleni Rettig; William R Ryan; Patrick K Ha; Hyunseok Kang; Justin Bishop; Harry Quon; Ana P Kiess; Jeremy D Richmon; David W Eisele; Carole Fakhry Journal: JAMA Oncol Date: 2017-02-01 Impact factor: 31.777
Authors: Zachary S Zumsteg; Galen Cook-Wiens; Emi Yoshida; Stephen L Shiao; Nancy Y Lee; Alain Mita; Christie Jeon; Marc T Goodman; Allen S Ho Journal: JAMA Oncol Date: 2016-12-01 Impact factor: 31.777
Authors: Joseph E Tota; William F Anderson; Charles Coffey; Joseph Califano; Wendy Cozen; Robert L Ferris; Maie St John; Ezra E W Cohen; Anil K Chaturvedi Journal: Oral Oncol Date: 2017-02-28 Impact factor: 5.972
Authors: Ari J Rosenberg; Evgeny Izumchenko; Alexander Pearson; Zhen Gooi; Elizabeth Blair; Theodore Karrison; Aditya Juloori; Daniel Ginat; Nicole Cipriani; Mark Lingen; Hillary Sloane; Daniel L Edelstein; Kirsten Keyser; Johannes Fredebohm; Frank Holtrup; Frederick S Jones; Daniel Haraf; Nishant Agrawal; Everett E Vokes Journal: BMC Cancer Date: 2022-01-03 Impact factor: 4.430
Authors: Melina J Windon; Gypsyamber D'Souza; Farhoud Faraji; Tanya Troy; Wayne M Koch; Christine G Gourin; Ana P Kiess; Karen T Pitman; David W Eisele; Carole Fakhry Journal: Cancer Date: 2019-01-15 Impact factor: 6.860
Authors: Jacob A Clarke; Alyssa M Despotis; Ricardo J Ramirez; Jose P Zevallos; Angela L Mazul Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-07-29 Impact factor: 4.090
Authors: Stephen Palasi; Ning Zhang; Mikaela Bankston; Joy Godby; Hannah Burrows; Jennifer Lagunas; William Perkison; Brandon Gunn; Mark S Chambers; David I Rosenthal; William Morrison; Adam Garden; Clifton David Fuller; Sharon Giordano; Eugene J Koay Journal: Clin Transl Radiat Oncol Date: 2021-08-08